The present disclosure relates to a cephalosporin antibacterial compound and a preparation method therefor. The cephalosporin antibacterial compound can exhibit antibacterial activity against Gram-negative bacteria and other bacteria.

The present disclosure relates to a cephalosporin antibacterial compound and a preparation method therefor. The cephalosporin antibacterial compound can exhibit antibacterial activity against Gram-negative bacteria and other bacteria.

A compound represented by formula (I), formula (II), or formula (IV), or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt thereof, for use in inhibiting metallo-?-lactamases.

Caged luciferin-based probes become a luciferase substrate emitting bioluminescence upon ?-lactamase/esterase activation. The inclusion of a cephalosporin moiety renders the probe capable of being used for the detection of a wide-range of ?-lactamases and ?-lactamase-expressing bacteria. Embodiments of a rapid high-throughput assay for the identification of ?-lactamase-expressing bacteria is made possible by the use of such probes. In some embodiments the cephalosporin is substituted by a carbapenem moiety to generate carbapenem-caged luciferin carbapenem-cleavable probes capable of being used for the detection of a wide-range of carbapenem-expressing bacteria. Accordingly embodiments of a rapid high-throughput assay for the identification of carbapenem-expressing bacteria is made possible by the use of these probes.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.

A novel crystalline form of Cefathiamidine compound and its preparation method, characterizing in its X-ray powder diffraction pattern and differential scanning calorimetry thermogram. Dissolving Cefathiamidine compound with a purity of 98% or higher in a solvent at a temperature of 3045 C. to form a solution, whose concentration is controlled within 0.050.2 g/mL, and then adding a solventing-out agent to the solution, wherein the amount of the solventing-out agent is 35 times (in volume) of that of the solvent; followed by cooling the solution down to 010 C. at a rate of 0.21 C./min; continuing to stir for 13 hours, and separating the obtained solid-liquid suspension to provide a novel crystalline form of Cefathiamidine compound after drying.